Company Overview
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $6.44M (-78.3% YoY); net profit $183.45M.
- Trailing 12 Months Year-on-year growth — revenue +36.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -20.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -20.57% |
| 1 Year: | 36.50% |
Stock Price Performance
| 1 Year: | -16.80% |
| 6 Months: | +11.99% |
| 3 Months: | +23.98% |
| 1 Month: | +13.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -20.6% CAGR over 5 years.
- Trading 33.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KYNB Kyntra Bio, Inc. PHARMA | 8.22 | -1.08 | $33.28M | 0.00% | -50.80% | - | -20.57% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 30.27M | 40.55M | 31.93M | 43.95M | 29.03M | 23.86M | 191.57M | 33.17M | 24.40M | 42.89M | 44.03M | 38.43M | 24.36M | 155.97M | 60.83M | 29.81M | 15.73M | 36.16M | 44.32M | 40.13M | 25.36M | 998.00K | 123.00K | 2.74M | 1.35M | 1.08M | 3.74M |
| Operating Income | -14.21M | 49.17M | -37.09M | -44.72M | 59.31M | -43.77M | -26.79M | 26.51M | -22.10M | -28.82M | -30.14M | -22.74M | -40.60M | -23.24M | -42.77M | -48.84M | 112.82M | -52.85M | -81.07M | -85.14M | 32.33M | -70.43M | -133.84M | 50.97M | -62.99M | -78.22M | -93.66M | -76.09M | -88.05M | -63.48M | -49.18M | -46.41M | -47.69M | -14.92M | -12.05M | -5.41M | -13.82M |
| Net Income | -16.24M | 46.83M | -39.53M | -46.37M | 57.05M | -45.10M | -27.84M | 24.32M | -24.15M | -30.61M | -31.91M | -24.46M | -41.40M | -23.42M | -42.56M | -45.41M | 116.00M | -49.44M | -78.35M | -85.31M | 33.00M | -71.75M | -133.99M | 49.80M | -63.20M | -72.62M | -91.65M | -76.70M | -87.68M | -63.62M | -32.93M | -15.54M | -17.08M | 4.64M | -7.60M | 200.64M | -15.20M |
| Diluted EPS | - | 0.58 | - | - | 0.83 | - | - | 0.35 | - | - | -0.48 | - | - | -0.28 | -0.50 | - | 1.26 | -0.57 | - | -0.95 | 0.35 | - | -1.45 | 0.54 | -0.68 | -0.78 | -0.98 | -0.81 | -0.90 | -0.65 | -0.33 | -3.89 | -4.25 | 1.15 | -1.88 | 49.61 | -3.76 |
| R&D Expense | 25.65M | 33.27M | 40.62M | 50.54M | 51.55M | 52.07M | 43.65M | 52.39M | 40.56M | 46.73M | 46.98M | 50.34M | 56.97M | 52.14M | 56.44M | 50.50M | 52.01M | 49.96M | 54.90M | 61.41M | 58.48M | 74.68M | 122.57M | 75.88M | 89.02M | 70.96M | 75.18M | 74.49M | 95.48M | 61.19M | 36.49M | 32.36M | 19.97M | 9.18M | 5.87M | 1.21M | 7.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.17M | 137.60M | 180.83M | 183.19M | 131.00M | 212.96M | 256.58M | 176.32M | 235.31M | 140.73M | 46.80M | 29.62M | 6.44M |
| Operating Income | -7.95M | -50.10M | -77.62M | -50.04M | -117.28M | -86.69M | -89.31M | -191.88M | -288.53M | -301.02M | -322.72M | -150.42M | -45.90M |
| Net Income | -14.94M | -59.50M | -85.78M | -58.07M | -120.88M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -284.23M | -47.58M | 183.45M |
| Diluted EPS | - | - | - | - | - | - | - | -2.11 | -3.14 | -3.14 | -2.92 | -11.89 | 45.37 |
| R&D Expense | 85.71M | 150.79M | 214.09M | 187.21M | 196.52M | 235.84M | 209.26M | 252.92M | 387.04M | 296.79M | 266.47M | 95.69M | 23.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Aug 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 483.53M | 470.57M | 469.55M | 898.65M | 880.60M | 857.40M | 826.84M | 773.82M | 610.09M | 423.53M | 214.53M | - | 119.59M |
| Total Equity | -46.25M | -60.83M | 221.41M | 177.55M | 155.84M | 528.47M | 509.20M | 516.13M | 422.18M | 209.15M | -21.45M | -204.17M | -225.60M | - | -30.04M |
| Cash & Equivalents | 38.87M | 76.33M | 165.46M | 153.32M | 173.78M | 673.66M | 89.26M | 126.27M | 678.39M | 171.22M | 155.70M | 81.55M | 50.48M | - | 47.87M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 75.00M | - |
| Total Liabilities | - | - | 242.85M | 273.75M | 294.44M | 350.91M | 352.13M | 321.99M | 385.39M | 544.71M | 611.57M | 585.73M | 398.16M | - | 115.12M |
| Current Liabilities | - | - | 62.75M | 67.18M | 65.12M | 85.96M | 89.03M | 102.75M | 163.19M | 225.50M | 273.56M | 217.67M | 133.31M | - | 29.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 7.11M | -66.51M | -76.14M | -78.70M | 81.60M | -82.23M | -145.93M | -315.02M | -138.00M | -4.77M |
| Investing Cash Flow | - | - | - | 6.62M | 69.87M | -522.12M | 120.02M | 452.49M | -426.97M | 89.12M | 153.66M | 125.99M | 35.42M |
| Financing Cash Flow | - | - | - | 6.74M | 496.47M | 13.88M | -4.30M | 13.34M | -563.00K | 46.78M | 122.75M | -255.00K | -86.03M |
| Capital Expenditure | -6.81M | -8.12M | -1.98M | -1.25M | -8.50M | -8.02M | -5.76M | -3.99M | -5.19M | -3.74M | -2.52M | -266.00K | -38.00K |
| Free Cash Flow | - | - | - | 5.86M | -75.01M | -84.16M | -84.47M | 77.61M | -87.42M | -149.67M | -317.54M | -138.26M | -4.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -7.8% | -36.4% | -42.9% | -27.3% | -89.5% | -40.7% | -34.8% | -108.8% | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% |
| Net Margin % | -14.6% | -43.2% | -47.4% | -31.7% | -92.3% | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2,848.6% |
| ROE % | 24.6% | -26.9% | -48.3% | -37.3% | -22.9% | -17.0% | -14.9% | -44.8% | -138.7% | 1,369.2% | 139.2% | 21.1% | -610.7% |
| ROCE % | - | -11.9% | -19.2% | -12.4% | -14.4% | -11.0% | -11.8% | -28.9% | -52.6% | -89.5% | -156.8% | -185.2% | -50.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.88% | 400.00K | $2.83M |
| 2 | Vanguard Capital Management LLC | 3.95% | 159.95K | $1.13M |
| 3 | Acadian Asset Management. LLC | 2.61% | 105.58K | $747.01K |
| 4 | Blackrock Inc. | 2.08% | 84.33K | $596.63K |
| 5 | Geode Capital Management, LLC | 1.07% | 43.22K | $305.77K |
| 6 | HighTower Advisors, LLC | 0.98% | 39.75K | $281.20K |
| 7 | Two Sigma Investments, LP | 0.98% | 39.51K | $279.54K |
| 8 | Renaissance Technologies, LLC | 0.67% | 27.08K | $191.60K |
| 9 | Vanguard Fiduciary Trust Co | 0.60% | 24.11K | $170.54K |
| 10 | Birchview Capital, LP | 0.56% | 22.57K | $159.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KYNB
How KYNB Company (KYNB) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOemZrS3ZHa1ctMVpZZ2dKWDNmeWhhY0dUTkJtbFlad3NUR0xFM0VLMnpXdzYxSk1XX282QnFkYkQ5aVVFdlliU1E2NTJuS2JvNWFJSVRoR3ZNZkxWWXF4cWNVR0xKZmRtS3dEcWhZcnZCY1FzNm9MbUdTcXNxQWU1dTNBNWI1bzhzV1EzMD…
A drug company's CEO will present in New York Sept. 15. Kyntra Bio will webcast it. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOM3RxQThBc24zN2Y3ZXB6SnR4ZFBlbXBHQmhhUDR5c2tuN1pVc2p3WTBuRnR4WlBqa3hQY0NUNV9PLXhzOFFqQkRBNFRCUkhLVmNMU0lLTVBNZDNJSjU1V09Xb3RIYTZER0RFMnZ4VloxMS1mRDY0b0lrOXVlMlowQVBXZ0dLc2l2TE1kR2…
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings | KYNB Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNQkNXaUctdEotWFhaQXVKekg5NTRyQWlUVzVaa1FON0R6aTZObFpPSHkzbzhQYUZzT25qT3EwVGFnNDBkVWQwaE9tWFBRVG53WEh1VS1YTlZNaE55TUZTRFZLdHd3STVkWlRBWEVacWIzelpjWlNETWMyYWlNeFpSM2drNA?oc=5" targe…
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFB3Y25OYU1SMFg1YVE5SVZfMzRYZlN0czduNDFVYzNrMUFBcFpfSkxScDcwOFZldUc2bF9SYXVoaEFYZFBPMDJvRG1NTHVSVUZGcjVpMkZ3?oc=5" target="_blank">Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News &…
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNTmRGV21CVDY0Z09WaldMb0p5OS1rSWRrZkZ3VkZ2c2VYbXBHX2ZfX1pEcGJZTnNGNUtTemthLTZMcGNYQTlOaE41X0FRaVV6WVZUekNtOFRKS0dYNDVHeTM4MFhHMUVKeS05UExPdGJmMkNUSi1BQk45WXZsd2YtYmpNMzUtcFdoSEtLcy…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1qNnRJclpuS1JQLVc4UFhXeHFRWmpMZ2dSd1JNUDNRVTlKN0hPamVjQmVLQlFMVGl6WGpSblo0aFpCM0hydUowZ1lhY0JqQm5R?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
KYNB — Frequently Asked Questions
What is the current share price of Kyntra Bio, Inc. (KYNB)?
As of 2026-09-19 21:16 PDT, Kyntra Bio, Inc. (KYNB) trades at $8.22 on NasdaqGS. Its 52-week range is $6.46 to $12.43.
What is the market capitalisation of KYNB?
Kyntra Bio, Inc. (KYNB) has a market capitalisation of $33.28M on NasdaqGS.
What is the P/E ratio of KYNB?
KYNB trades at a trailing price-to-earnings (P/E) ratio of -1.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.95.
Is KYNB a good stock to buy?
This page provides a data-driven analysis of Kyntra Bio, Inc. (KYNB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.